Pacific Biosciences of California, Inc. Share Price
Stocks
PACB
US69404D1081
Advanced Medical Equipment & Technology
|
Market Closed -
Nasdaq
21:00:00 10/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 2.240 USD | -5.08% |
|
-8.20% | +19.79% |
| 11-09 | UBS Adjusts Price Target on Pacific Biosciences of California to $2.70 From $3.05, Maintains Neutral Rating | MT |
| 11-05 | Pacific Biosciences of California, Inc., Q3 2026 Earnings Call, Nov 04, 2026 |
| Market Cap | 701M 629M 579M 526M 996M 65.72B 1.02B 6.94B 2.76B 35.21B 2.63B 2.57B 111B | P/E 2026 * |
-5.38x | P/E 2027 * | -4.7x |
|---|---|---|---|---|---|
| Enterprise Value | 1.17B 1.05B 964M 876M 1.66B 109B 1.7B 11.54B 4.6B 58.59B 4.38B 4.28B 185B | EV / Sales 2026 * |
7.41x | EV / Sales 2027 * | 6.8x |
| Free-Float |
91.4% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| PACB | Delayed | |
CBOE
| PACB | Real-time | |
|
Tradegate
| P09 | Real-time | |
|
Mexican S.E.
| PACB * | End-of-day quote | |
|
Deutsche Boerse AG
| P09 | Delayed | |
|
Börse Stuttgart
| P09 | Delayed | |
|
Boerse Muenchen
| P09 | Real-time | |
|
Xetra
| P09 | Delayed |
Last Transcript: Pacific Biosciences of California, Inc.
| 1 day | -5.08% | ||
| 1 week | -8.20% | ||
| Current month | -14.01% | ||
| 1 month | -3.86% | ||
| 3 months | +94.78% | ||
| 6 months | +58.87% | ||
| Current year | +19.79% |
| 1 week | 2.12 |  | 2.69 |
| 1 month | 1.7 | | 3.06 |
| Current year | 1.07 | | 3.44 |
| 1 year | 1.07 | | 3.44 |
| 3 years | 0.85 | | 10.65 |
| 5 years | 0.85 | | 28.17 |
| 10 years | 0.85 | | 53.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark van Oene
CEO | Chief Executive Officer | 53 | 04/08/2026 |
Jonas Korlach
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2012 |
Todd Friedman
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Bill Ericson
BRD | Director/Board Member | 67 | 31/12/2003 |
Randy Livingston
BRD | Director/Board Member | 72 | 31/12/2008 |
Marshall Mohr
BRD | Director/Board Member | 69 | 17/01/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/10/26 | Exercice | Chief Financial Officer | 1,661,815 | 0.5346% | ||
| 17/08/26 | Sell | Chief Executive Officer | -26,911 | 0.0087% | ||
| 10/08/26 | Free | Chief Executive Officer | 2,457,018 | 0.7911% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.08% | -8.20% | +27.27% | -65.64% | 701M | |
| -0.48% | +2.84% | +24.61% | +60.16% | 266B | |
| +0.42% | +2.61% | +11.81% | +19.85% | 166B | |
| -2.28% | +2.11% | -21.90% | +62.18% | 156B | |
| +1.54% | +2.76% | -55.70% | -13.30% | 64.79B | |
| -0.67% | +9.27% | +23.70% | +61.98% | 59.81B | |
| +0.71% | -0.95% | -0.97% | -9.81% | 53.3B | |
| -1.27% | +1.38% | +21.54% | +63.99% | 50.15B | |
| -0.28% | +0.77% | +3.31% | +85.09% | 49.47B | |
| -0.25% | +3.40% | +26.28% | +85.81% | 46.72B | |
| Average | -0.77% | +1.95% | +6.00% | +35.03% | 91B | |
| Weighted average by Cap. | -0.45% | +2.99% | +5.85% | +46.77% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 157M 141M 130M 118M 224M 14.76B 230M 1.56B 621M 7.91B 591M 578M 25B | 179M 161M 148M 135M 255M 16.82B 262M 1.78B 707M 9.01B 673M 659M 28.49B |
| Net income | -130M -116M -107M -97.4M -184M -12.17B -189M -1.28B -512M -6.52B -487M -477M -20.61B | -146M -131M -120M -109M -207M -13.66B -213M -1.44B -575M -7.32B -547M -535M -23.14B |
| Net Debt | 466M 417M 385M 349M 661M 43.64B 680M 4.61B 1.84B 23.38B 1.75B 1.71B 73.92B | 518M 465M 428M 389M 736M 48.6B 757M 5.13B 2.04B 26.04B 1.95B 1.9B 82.31B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/11/26 | US$2.240 | -5.08% | 8,885,081 |
| 09/11/26 | US$2.360 | +4.66% | 11,843,401 |
| 06/11/26 | US$2.255 | -7.20% | 9,564,171 |
| 05/11/26 | US$2.430 | -4.71% | 20,583,853 |
| 04/11/26 | US$2.550 | +4.51% | 20,974,348 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- PACB Stock
Select your edition
All financial news and data tailored to specific country editions
